-
Dr. Hou Ming: BTK Inhibitor Ibrutinib Offer Limitless Prospects for ITP Treatment
Editor’s Note: From June 8th to 11th, 2023, the 28th European Hematology Association (EHA) Congress was held in Frankfurt, Germany. During this conference, Dr. Hou Ming’s team at Qilu Hospital, Shandong University, China, presented the research findings on the use of the BTK inhibitor ibrutinib for primary immune thrombocytopenia (ITP) (abstract S299). To gain deeper…
-
Dr. Amir Fathi: The Latest Advances in Targeted Therapy for Acute Myeloid Leukemia
Abstract: In this interview, Dr. Amir Fathi provides insights into the impact of NPM1 mutations on the prognosis of acute myeloid leukemia (AML) patients, emphasizing the evolving nuances based on…
-
Dr. Ma Jun: Immunotherapy Progress and Future Trends in Acute Lymphoblastic Leukemia
Editor’s Note: The 28th European Hematology Association (EHA) Congress, held from June 8th to June 11th, 2023, in Frankfurt, Germany, presented a combination of online and offline formats. As the…
-
Dr. WeipingCai: Long-Acting Antiretroviral Drugs Usher in a New Chapter in AIDS Care
Infectious Disease Frontier specially invited Dr. Weiping Cai from the Eighth Affiliated Hospital of Guangzhou Medical University, China, to provide insightful comments on this hot research area.
-
SABCS 2023丨An Interview with Dr. Santiago Escriva-de-Romanion the Novel Zaniratamab Combinations for HR+/HER2+ mBC
Oncology Frontier: Thank you for joining us, Dr. Santiago Escriva-de-Romani. We are excited to discuss the introduction of a new track in breast cancer treatment, particularly focusing on the novel anti-HER2…
-
SABCS 2023丨Treatment Approach for Leptomeningeal Carcinomatosis in Advanced Breast Cancer Patients: Antibody-Drug Conjugate Trastuzumab Deruxtecan
Oncology Frontier: Thank you for joining us. Could you please share the key results from DEBBRAH Study? Dr. Marta Vaz Batista : Certainly. DEBBRAH is a phase 2 trial, an investigator-initiated trial, funded by METZIR…
Connecting Medical Expertise through Media
